Belite Bio Announces U.S. Food and Drug Administration Acceptance And Priority Review Of New Drug Application For Tinlarebant For The Treatment Of Stargardt Disease Type 1
BLTE•FDA accepts NDA and sets review date
- Belite Bio, Inc. BLTE.O said the U.S. Food and Drug Administration accepted and granted priority review of its new drug application for tinlarebant for the treatment of Stargardt disease type 1.
- Belite Bio said the FDA set a PDUFA date of February 12, 2027 for the tinlarebant NDA.
